1. Home
  2. AMTB vs GLUE Comparison

AMTB vs GLUE Comparison

Compare AMTB & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

N/A

Current Price

$29.19

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

N/A

Current Price

$11.25

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMTB
GLUE
Founded
1979
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
AMTB
GLUE
Price
$29.19
$11.25
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
★ $31.88
$28.50
AVG Volume (30 Days)
282.6K
★ 949.3K
Earning Date
10-22-2026
11-05-2026
Dividend Yield
★ 1.26%
N/A
EPS Growth
★ 386.36
N/A
EPS
★ 0.97
N/A
Revenue
N/A
★ $123,672,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.20
N/A
P/E Ratio
★ $30.06
$72.42
Revenue Growth
N/A
★ 63.54
52 Week Low
$15.62
$7.24
52 Week High
$30.60
$25.77

Technical Indicators

Market Signals
Indicator
AMTB
GLUE
Relative Strength Index (RSI) 47.22 28.92
Support Level $28.31 N/A
Resistance Level $30.19 $15.00
Average True Range (ATR) 0.78 0.59
MACD -0.11 0.05
Stochastic Oscillator 25.67 9.06

Price Performance

Historical Comparison
AMTB
GLUE

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: